The HFA-ICOS risk tool separates patients by the planned systemic anti-cancer treatment (anthracycline, HER2, VEGF inhibitors, RAF/MEK tyrosine kinase inhibitors, multiple-myeloma therapies, multi-target kinase inhibitors for CML). This evidence concerns the gene ERBB2 and cancer.